Q&A: Smoking and Inflammation in Axial Spondyloarthritis

July 30, 2020

Patients with axial spondyloarthritis who smoke may be more likely to have sacroiliac joint inflammation if they have a blue‐collar job or low education, according to a study recently published in Arthritis & Rheumatology. In this Q&A with study author Elena Nikiphorou, M.B.B.S./B.Sc., M.D.(Res), Consultant Rheumatologist at King's College Hospital in London, U.K.,we discuss the study and its findings.

Q&A: BMI Link to Disease Activity in Axial Spondyloarthritis

July 30, 2020

Patients with axial spondyloarthritis may be more susceptible to higher disease activity if they are overweight or obese, according to a systematic review and meta-analysis published in RMD Open. In this Q&A with study author Jean Liew, M.D., of University of Washington in Seattle, we discuss the study and its significance.

SpA Cases Flare Under COVID-19 Due to Misinformation

June 23, 2020

French researchers writing in Arthritis and Rheumatology report that of 609 surveyed spondyloarthritis patients self-isolating at home due to COVID-19, most say their condition has progressed while in isolation and for some, the change has been considerable.

EULAR Report: Dual Cause of Increased CV Risk in Ankylosing Spondylitis Needs Attention

June 08, 2020

The increased cardiovascular disease risk in patients with ankylosing spondylitis is explained both by traditional  cardiovascular risk factors as well as the underlying chronic inflammatory process. However, this dual etiology is not adequately addressed in clinical practice, according to a presentation on June 3 at the European Congress of Rheumatology (EULAR) annual meeting.

EULAR Report: Cesarean Deliveries Higher in Spondyloarthritis

June 08, 2020

Spondyloarthritis is associated with an increased risk of preterm births, small gestational age infants and elective cesarean section deliveries, according to study data presented on June 4 at the European Congress of Rheumatology (EULAR) annual meeting.

EULAR Report: Ixekizumab Approved for Axial Spondyloarthritis

June 04, 2020

Eli Lilly announced this week that Taltz (ixekizumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA). And, this week during the EULAR annual meeting, the company is reporting results from the 52-week SPIRIT phase 3b/4 trial for psoriatic arthritis comparing ixekizumab to adalimumab.

Medication, Stress Management in Rheumatology Patients During the COVID-19 Pandemic

May 08, 2020

Writing in Practical Pain Management, Don L. Goldenberg, M.D., addresses clinical approaches for managing medications during the COVID-19 pandemic in patients with chronic rheumatic autoimmune disease.

Q&A with Dr. Nigil Haroon: COVID-19 and Spondyloarthritis

May 08, 2020

In this Q&A with rheumatologist Nigil Haroon, M.D., Ph.D., of the University Health Network and Krembil Research Institute at the University of Toronto, we discuss COVID-19 factors specific to patients with spondyloarthritis.

TNFi Dose Reduction Shows No Benefit for Spondyloarthritis

April 07, 2020

A new study shows there is little to no clinical benefit in reducing TNFi treatment dosages for patients with axial spondyloarthritis (axSpA).

Impaired Microbiota May Lead to Spondyloarthritis

April 06, 2020

A comprehensive review of published studies on gut microbiota, immunity and arthritis suggests that having a microbial imbalance may precede the development of spondyloarthritides and osteoarthritis.